

Callitas Health, Inc., Signs a Definitive Patent Technology Assignment Agreement to Acquire Additional Novel Cannabis Dosing Technologies

CINCINNATI, OH, October 2, 2018 – [Callitas Health Inc.](#) (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development, OTC consumer goods marketing and cannabis delivery development company, today announced that it signed a definitive Patent Technology Assignment Agreement with Ronald J. Thompson, MD to expand its cannabis delivery technology portfolio. The new intellectual property acquired (four separate patent applications) will cover various novel oral and ingestible products including those for orally dissolving immediate cannabis effect, sustained release cannabis effect, and a combination of both. It will also cover products for the appropriate individual controlled dosing of CBD and/or THC for the legal, adult use and medical marijuana markets.

"Using our clinically-proven delivery technology, pharmaceutical development and intellectual property experience, we have developed and acquired multiple new patent applications that define and protect a continuum of novel advanced cannabis dosing technologies," said Callitas CEO, James Thompson. "These new delivery and dosing technologies will create a new platform of products for both the legal, medical and adult-use cannabis markets. We will apply pharmaceutical best practices to the cannabis markets in developing products with the newly acquired technologies."

"The potential benefits of these types of products is immense," said Chief Medical Cannabis Advisor, Dr. Gregory Smith MD, MPH. "The team at Callitas has been focused on acquiring and bringing innovative technologies to the market, and these new proprietary products fit right into the Company's mission of bringing pharmaceutical best practices to the cannabis space through controlled dosing, improved bioavailability and advanced manufacturing techniques."

The agreement with Dr. Thompson provides for full assignment of the intellectual property rights, including patents pending, any patents to be filed in the future and any/all trade secrets and proprietary information, in the Cannabis dosing space, to Callitas Health Inc., in exchange for a high single-digit royalty on Net Sales or Net Proceeds from the assigned/licensed technology.

About Ronald J. Thompson, MD: Dr. Thompson has brought a patient-first mindset to all his endeavors. Improving patient outcomes has been the driving force behind all of Dr. Thompson's inventions, developments and patient care in the last 40 years. He has been a member of the American Fertility Society since 1988 and is also a Fellow of the American College of Obstetricians and Gynecologists and a Diplomat of American Board of Obstetrics and Gynecology. Dr. Thompson holds more than 40 issued U.S. medical device, drug and drug delivery patents.

About Callitas Health: Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on

developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J's LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive (www.toconceive.com), and is in the research and development and business development process for its other OTC products, cannabis dosing technologies and orphan drug technologies. For more information visit www.callitas.com.

Contacts:

Callitas Health:

James Thompson, CEO, or

Callitas Investor Relations

Phone: +1 (859) 868-3131

TraDigitalIR:

Investor Relations – Kevin McGrath, Managing Director

Phone: +1 (646) 418-7002

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company's biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body. Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.